Potential conflict of interest: Nothing to report.
Is disease recurrence still relevant to graft survival?
Article first published online: 24 OCT 2013
© 2013 American Association for the Study of Liver Diseases
Special Issue: Liver Transplantation – First Quarter, Second Decade
Volume 19, Issue S2, pages S49–S55, November 2013
How to Cite
Trotter, J. F. (2013), Is disease recurrence still relevant to graft survival?. Liver Transpl, 19: S49–S55. doi: 10.1002/lt.23750
- Issue published online: 24 OCT 2013
- Article first published online: 24 OCT 2013
- Accepted manuscript online: 23 SEP 2013 07:16AM EST
- Manuscript Accepted: 5 SEP 2013
- Manuscript Received: 10 JUN 2013
- 1Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2011 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2012.
- 5A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C group [abstract]. J Hepatol 2013;58(suppl 1):S10-S11., , , , , , et al.
- 7Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010;16:431-439., , , , .
- 8Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl 2013;19:268-274., , , , .
- 10Living related liver transplant (LRLT) in HBV DNA negative cirrhosis without hepatitis B immune globulin (HBIG) [abstract]. Hepatol Int 2011;5:S38., , , , , , et al.